Back to News & Events

Sustained Nano Systems Reports Positive In-Vitro Results Glaucoma Treatment

March 8, 2018

SUSTAINED NANO SYSTEMS ACHIEVES POSITIVE IN-VITRO RESULTS ON LONG TERM SUSTAINED DELIVERY OF LATANAPROST FOR GLAUCOMA TREATMENT.

New York, NY – March 6, 2018 (NEWSFRONT MEDIA). Sustained Nano Systems, LLC (“SNS”), a biopharmaceutical company utilizing its platform technology of bio-resorbable nano and microparticles for long term drug delivery, is pleased to announce positive results for the in-vitro presence of Latanaprost for the treatment of glaucoma over a duration of 159 days.

Latanaprost, a prostaglandin analogue, is the #1 glaucoma drug in the world, with dosing of up to four eye drops every day for the remainder of a patient’s life. Latanaprost reduces elevated intraocular pressure in open-angle glaucoma or ocular hypertension. At the present time, there is no long-acting formulation for glaucoma, only multiple daily eyedrops. SNS LAT-LA (Latanaprost Long Acting) is designed to be administered by a single periocular injection with a duration of six months. “The potential for SNS LAT-LA to sustain deliver for six months, would fulfill an important unmet need in replacing the more burdensome and potentially less compliant regimen of daily eye drops,” said Dr. Barry Libin, CEO of SNS. LAT-LA will now undergo further studies to indicate its efficacy in the long term reduction of intra-ocular pressure.

Glaucoma is the second leading cause of blindness in the world, in which abnormally high intraocular pressure may cause damage to the optic nerve, resulting in irreversible vision loss. In the U.S. alone, 2.7 million people suffer from glaucoma. According to IMS Health data, there were 34 million prescriptions and sales of over $2.7 billion of drugs administered by eye drops for the treatment of glaucoma in the U.S. in 2017, and global spending was over $6 billion. Compliance is the biggest problem with existing therapies for glaucoma, with more than 50% of patients on topical prostaglandin analogs not compliant within the first six months of treatment

ABOUT SUSTAINED NANO SYSTEMS (SNS)

SNS is a privately held biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions in ophthalmology, oncology and other areas. The Company’s research facility is located on the campus of Stony Brook University as part of the Long Island High Technology Incubator. The SNS platform is the result of a comprehensive research effort that allows for long term micro-dosing for the continuous release of drugs to targeted tissues as prescribed. The basis of the SNS pipeline is its patented technology that incorporates bio-resorbable nano and micro carriers to deliver sustained delivery of important therapeutics, including anti-inflammatories and monoclonal antibodies for immunotherapies in cancer, retinal disease, and other disease states.

For further information, visit: www.sustainednanosystems.net

Forward-Looking Statements
SNS Disclosure Notice: This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “would,” “estimate,” or “continue,” or the negative or other variations thereof or comparable terminology are intended to identify forward looking statements. Investors are cautioned that all forward looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company’s ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company’s control.

Investors are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Contact:

Dr. Barry Libin  (516) 353‐7983, barlibin@gmail.com
Media Relations: info@newsfrontmedia.com

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4906
                    [post_author] => 4
                    [post_date] => 2025-07-17 10:27:09
                    [post_date_gmt] => 2025-07-17 14:27:09
                    [post_content] => 

The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.





The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.





“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”





Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”





The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.





“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.





As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.





Dowload the full press release here. 







                    [post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => redesignation2025
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-07-21 14:51:44
                    [post_modified_gmt] => 2025-07-21 18:51:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=4906
                    [menu_order] => 0
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 4488
                    [post_author] => 4
                    [post_date] => 2024-10-24 10:45:00
                    [post_date_gmt] => 2024-10-24 14:45:00
                    [post_content] => 

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.





The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.





New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.





A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.





New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.





Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy


                    [post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-02-26 16:35:20
                    [post_modified_gmt] => 2025-02-26 21:35:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=4488
                    [menu_order] => 0
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 2899
                    [post_author] => 1
                    [post_date] => 2017-12-15 20:24:05
                    [post_date_gmt] => 2017-12-15 20:24:05
                    [post_content] => Clinton Rubin, PhD, Director of the Center for Biotechnology and Distinguished Professor of Biomedical Engineering at Stony Brook University has been elected as a Fellow of the National Academy of Inventors (NAI). According to the NAI, election as an NAI Fellow is a high honor bestowed upon academic innovators and inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions and innovations that have made a tangible impact on quality of life, economic development, and the welfare of society. Dr. Rubin and fellow SBU Distinguished Professor Dr. Arie Kaufman will be inducted as NAI Fellows during its 2018 national meeting in Washington, DC, on April 5.

With the election of the 2017 class there are now 912 NAI Fellows, representing over 250 research universities and governmental and non-profit research institutes. The 2017 Fellows are named inventors on nearly 6,000 issued U.S. patents, bringing the collective patents held by all NAI Fellows to more than 32,000 issued U.S. patents.

Professor Rubin, founding chair of Stony Brook’s Department of Biomedical Engineering, pioneered research in understanding the role of mechanical signals in the musculoskeletal system and has patented technology that includes use of low frequency mechanical signals (vibrations) to combat disease like osteoporosis and obesity.

More on Dr. Rubin’s election as an NAI Fellow can be access here and here.
                    [post_title] => CFB Director Elected Fellow, National Academy of Inventors (NAI)
                    [post_excerpt] => Clinton Rubin, PhD, Director of the Center for Biotechnology has been elected a Fellow of the National Academy of Inventors (NAI).
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => cfb-director-elected-fellow-national-academy-of-inventors-nai
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2018-01-23 14:38:34
                    [post_modified_gmt] => 2018-01-23 14:38:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => http://centerforbiotechnology.org/?p=2899
                    [menu_order] => 131
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 2210
                    [post_author] => 3
                    [post_date] => 2016-05-12 19:03:22
                    [post_date_gmt] => 2016-05-12 19:03:22
                    [post_content] => TheraSource LLC, a Feinstein Institute for Medical Research spin-out, has received a $3 million three-year Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH). The grant will support the development of human ghrelin as an innovative treatment to alleviate health damage caused by unintentional radiation exposure.

TheraSource has been a client of the Center for Biotechnology and the organization is proud to have played an integral role in the helping the company advance their business and technology strategy. As noted by Diane Fabel, Director of Operations for the Center for Biotechnology, “The Phase II award for TheraSource is a significant landmark for the company and an important milestone for the region.”

Ping Wang, MD, founder of TheraSource and Chief of Scientific Officer (CSO) of the Feinstein Institute has stated “Human ghrelin has been investigated in clinical trials of other indications.  With our new findings, we will soon be able to file an Investigational New Drug application to US Food and Drug Administration,” said Dr. Wang. “TheraSource has received investments to fund its various projects and is seeking strategic partnerships towards the goal of clinical development and commercialization.”

For more details, read the company’s press release here.
                    [post_title] => TheraSource LLC receives $3M SBIR Grant
                    [post_excerpt] => TheraSource LLC, a Feinstein Institute for Medical Research spin-out, has received a $3 million three-year Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH). 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => therasource-llc-receives-3m-sbir-grant
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2016-05-12 19:13:45
                    [post_modified_gmt] => 2016-05-12 19:13:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => http://centerforbiotechnology.org/?p=2210
                    [menu_order] => 181
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [4] => WP_Post Object
                (
                    [ID] => 4272
                    [post_author] => 4
                    [post_date] => 2023-08-28 13:39:39
                    [post_date_gmt] => 2023-08-28 17:39:39
                    [post_content] => 

The Long Island BioMentor Initiative (LIBMI), created and managed by the Center for Biotechnology, is excited to welcome two new mentors, Dr. Annie Rohan, PhD, RN, FAANP, FAAN and Mike Horan, MBA.





Dr. Annie Rohan is currently Dean of the Henry P. Becton School Nursing and Allied Health at Fairleigh Dickinson University. Dr. Rohan is a dual-certified Nurse Practitioner whose academic achievements rest on the foundation of a 25-year clinical career caring for critically and chronically ill infants and children, and highest-risk families. To support diversification of the healthcare workforce, she has procured over $10-million in federal funding to support the education of underrepresented and disadvantaged students into the allied health and nursing professions. Dr. Rohan is currently Associate Editor for MCN: The American Journal of Maternal-Child Nursing, and has been honored with Fellowship in both the American Academy of Nurse Practitioners (FAANP) and American Academy of Nursing (FAAN).





Mike Horan, MBA is a Product Development, Engineering, and Operations Executive. He is an accomplished engineering and technology business leader with over 30 years of experience in product development. At Zebra Technologies, he currently serves as the Sr. Director of Global Quality overseeing quality for their product and solutions portfolio, supply chain and QMS. Mike has experience in Strategic & Portfolio Planning, Engineering Leadership, Program Management, Supply Chain, Manufacturing and Operations —all in a global environment. He is a highly motivational leader with experience in building high-performing teams.





The LIBM brings highly qualified volunteer mentors together with motivated, early-stage bioentrepreneurs to provide actionable guidance and support as they advance their business strategy. The initiative was developed in an alliance with MIT’s successful Venture Mentor Service and employs a team mentoring approach which is guided by a statement of principles to ensure confidentiality and a conflict free environment. 





To learn more about the program or get involved, visit the LIBMI website or contact Ashley Abid, LIBMI Operations Manger (ashley.abid@stonybrook.edu)


                    [post_title] => Long Island BioMentor Initiative Welcomes New Mentors
                    [post_excerpt] => Dr. Anne Rohan and Mr. Mike Horan have joined the esteem rosters of mentors among the Long Island BioMentor Initiative.
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => new-mentors-libmi-0823
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-22 11:37:59
                    [post_modified_gmt] => 2024-08-22 15:37:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=4272
                    [menu_order] => 0
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [post_count] => 5
    [current_post] => -1
    [before_loop] => 1
    [in_the_loop] => 
    [post] => WP_Post Object
        (
            [ID] => 4906
            [post_author] => 4
            [post_date] => 2025-07-17 10:27:09
            [post_date_gmt] => 2025-07-17 14:27:09
            [post_content] => 

The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.





The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.





“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”





Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”





The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.





“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.





As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.





Dowload the full press release here. 







            [post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => open
            [ping_status] => open
            [post_password] => 
            [post_name] => redesignation2025
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2025-07-21 14:51:44
            [post_modified_gmt] => 2025-07-21 18:51:44
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => https://centerforbiotechnology.org/?p=4906
            [menu_order] => 0
            [post_type] => post
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [comment_count] => 0
    [current_comment] => -1
    [found_posts] => 274
    [max_num_pages] => 92
    [max_num_comment_pages] => 0
    [is_single] => 
    [is_preview] => 
    [is_page] => 
    [is_archive] => 
    [is_date] => 
    [is_year] => 
    [is_month] => 
    [is_day] => 
    [is_time] => 
    [is_author] => 
    [is_category] => 
    [is_tag] => 
    [is_tax] => 
    [is_search] => 
    [is_feed] => 
    [is_comment_feed] => 
    [is_trackback] => 
    [is_home] => 1
    [is_privacy_policy] => 
    [is_404] => 
    [is_embed] => 
    [is_paged] => 
    [is_admin] => 
    [is_attachment] => 
    [is_singular] => 
    [is_robots] => 
    [is_favicon] => 
    [is_posts_page] => 
    [is_post_type_archive] => 
    [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
    [query_vars_changed:WP_Query:private] => 
    [thumbnails_cached] => 
    [allow_query_attachment_by_filename:protected] => 
    [stopwords:WP_Query:private] => 
    [compat_fields:WP_Query:private] => Array
        (
            [0] => query_vars_hash
            [1] => query_vars_changed
        )

    [compat_methods:WP_Query:private] => Array
        (
            [0] => init_query_flags
            [1] => parse_tax_query
        )

    [query_cache_key:WP_Query:private] => 
)

Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology

July 17, 2025

More Information

Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

October 24, 2024

More Information

CFB Director Elected Fellow, National Academy of Inventors (NAI)

December 15, 2017

More Information

TheraSource LLC receives $3M SBIR Grant

May 12, 2016

More Information

Long Island BioMentor Initiative Welcomes New Mentors

August 28, 2023

More Information